AI-Native Scoping Reviews & Evidence Mapping

This paper shows that DCB is not just a technical upgrade over POBA, but a consistently stronger strategy for restenosis-prone vascular disease, with better patency and fewer repeat interventions across coronary ISR, femoropopliteal lesions, BTK disease, and dialysis access. The full paper is worth reading because it reveals where that advantage is most convincing, where technique and vessel preparation change the outcome, and how much of DCB’s real-world value lies in selecting the right lesion, not just the device.

The paper tackles one of endovascular medicine’s most controversial questions: whether DCBs truly carry a late mortality risk. Mapping 170 original studies, it shows why the feared signal largely fades in broader evidence, where comorbidity and indication matter more than the device itself — and reveals the few settings where uncertainty still remains.

This paper shows that daylight saving time is not a harmless calendar ritual: the clock changes align with measurable spikes in mortality, suicide, cardiovascular events, sleep loss, and road danger, with the spring and autumn transitions carrying distinct risks. Read the full paper to see where the strongest signals emerge, which outcomes remain inconsistent, and why the evidence increasingly points toward ending biannual clock changes rather than treating them as a neutral social habit.

CLTI/CLI is not always the end of the road: this review maps the emerging alternatives that may help selected “no-option” patients avoid or delay amputation, from cell and gene therapy to venous arterialization, retrograde access, and adjunctive pharmacology. The full paper shows where the evidence is clinically promising, where it remains experimental, and which strategies may realistically enter limb-salvage practice next.

Some of the most dangerous cracked teeth are the ones that still look normal. This review shows why early recognition and timely cuspal protection matter — before a subtle crack becomes a restorative and biologic disaster.

This review maps 260 original studies and 80,624 participants into a practical evidence layer on where coil embolization helps in aortic aneurysm repair — especially type II endoleak prevention, sac behavior, and staged spinal-cord-protection strategies. It also shows the trade-offs that matter clinically: recurrent endoleaks, buttock claudication, radiation exposure, infection risk, coil migration, and when coils, plugs, Onyx, NBCA, or anatomy-driven alternatives may be preferable.

This paper shows that coffee is not a proven anti-aging therapy, yet the mapped evidence still suggests a biologically plausible link to longer survival through oxidative-stress and insulin/IGF-1 pathways, with human data pointing to modest benefit rather than clear harm. Read the full text to see where the real signal lies, which findings are only indirect or genotype-specific, and why the apparent longevity story of coffee is much more nuanced than popular health claims suggest.

CLTI prognosis is not decided by the artery alone: this evidence map shows that wound severity, nutrition, frailty, heart failure, dialysis, mobility loss, and biomarkers together define who survives, heals, or loses a limb. The full review explains which clinical scores and warning signals may help identify high-risk patients before revascularization decisions are made.

This paper shows that vascular calcification in CKD is not a passive byproduct of renal failure, but an active, biologically driven process fueled by phosphate burden, uremic toxins, inflammation, and VSMC transdifferentiation. The full paper is worth reading because it maps where the strongest mechanistic and clinical signals converge across 1,230 original studies, and highlights which biomarkers and interventions may actually become actionable in routine CKD care.

Y chromosome loss emerges in this paper not as a passive marker of ageing, but as a potentially central male-specific biological signal linked to cardiovascular death, cancer progression, neurodegeneration, and immune dysfunction across a massive evidence base. The full paper is worth reading because it shows where this signal is strongest, how consistent it is across 1,048 original studies, and why LOY may become both a prognostic biomarker and a future therapeutic target.

This paper shows that the choice between carotid endarterectomy and carotid stenting is not just a technical preference, but a clinically meaningful trade-off between stroke risk, myocardial infarction risk, and long-term durability. Read the full paper to see which patients truly benefit from CEA as the default option, where CAS still has a justified role, and how 670 original studies map the evidence behind that decision.